Seres Therapeutics (MCRB) Current Assets (2014 - 2026)
Seres Therapeutics (MCRB) posted Current Assets of $31.8 million for Q1 2026, down 35.52% sequentially from $49.4 million in Q4 2025, and down 51.82% YoY from $66.1 million in Q1 2025.
Seres Therapeutics (MCRB) Current Assets (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Current Assets for 13 years, with the latest figure at $31.8 million in Q1 2026.
- Quarterly Current Assets fell 51.82% year-over-year to $31.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.8 million (down 51.82% YoY) and the FY2025 annual result came in at $49.4 million, up 27.67% from the prior year.
- Current Assets fell to $31.8 million in Q1 2026 per MCRB's latest filing, from $49.4 million in the prior quarter.
- Over five years, Current Assets peaked at $263.2 million in Q1 2022 and troughed at $31.8 million in Q1 2026.
- A 5-year average of $138.0 million and a median of $149.3 million in 2024 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 42.3% in 2024, down 77.95% in 2024.
- Over 5 years, Current Assets stood at $194.8 million in 2022, then dropped by 9.94% to $175.4 million in 2023, then slumped by 77.95% to $38.7 million in 2024, then climbed by 27.67% to $49.4 million in 2025, then tumbled by 35.52% to $31.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $31.8 million, $49.4 million, and $51.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 1.76 Bn |
| 10 | Seres Therapeutics | 44.16 Mn | 44.16 Mn | - | 42.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.35 Mn |
| Mar 31, 2026 | 31.84 Mn |
| Dec 31, 2025 | 49.38 Mn |
| Sep 30, 2025 | 51.53 Mn |
| Jun 30, 2025 | 48.69 Mn |
| Mar 31, 2025 | 66.08 Mn |
| Dec 31, 2024 | 38.67 Mn |
| Sep 30, 2024 | 72.93 Mn |
| Jun 30, 2024 | 149.27 Mn |
| Mar 31, 2024 | 165.18 Mn |
| Dec 31, 2023 | 175.41 Mn |
| Sep 30, 2023 | 214.39 Mn |
| Jun 30, 2023 | 251.24 Mn |
| Mar 31, 2023 | 116.08 Mn |
| Dec 31, 2022 | 194.76 Mn |
| Sep 30, 2022 | 247.51 Mn |
| Jun 30, 2022 | 209.58 Mn |
| Mar 31, 2022 | 263.25 Mn |
| Dec 31, 2021 | 303.63 Mn |
| Sep 30, 2021 | 358.81 Mn |